FRONT PAGE AMPYRA AUBAGIO AVONEX BETASERON COPAXONE EXTAVIA
Stan's Angels MS News Channel on YouTube GILENYA NOVANTRONE REBIF RITUXAN TECFIDERA TYSABRI
 Daily News for Neuros, Nurses & Savvy MSers: 208,152 Viewers, 8,368 Stories & Studies
Click Here For My Videos, Advice, Tips, Studies and Trials.
Timothy L. Vollmer, MD
Department of Neurology
University of Colorado Health Sciences Center Professor

Co-Director of the RMMSC at Anschutz Medical Center

Medical Director-Rocky Mountain MS Center
Click here to read my columns
Brian R. Apatoff, MD, PhD
Multiple Sclerosis Institute
Center for Neurological Disorders

Associate Professor Neurology and Neuroscience,

Weill Medical College of Cornell University

Clinical Attending in Neurology,
New York-Presbyterian Hospital
CLICK ON THE RED BUTTON BELOW
You'll get FREE Breaking News Alerts on new MS treatments as they are approved
MS NEWS ARCHIVES: by week

HERE'S A FEW OF OUR 6000+ Facebook & MySpace FRIENDS
Timothy L. Vollmer M.D.
Department of Neurology
University of Colorado Health Sciences Center
Co-Director of the RMMSC at Anschutz Medical Center
and
Medical Director-Rocky Mountain MS Center


Click to view 1280 MS Walk photos!

"MS Can Not
Rob You of Joy"
"I'm an M.D....my Mom has MS and we have a message for everyone."
- Jennifer Hartmark-Hill MD
Beverly Dean

"I've had MS for 2 years...this is the most important advice you'll ever hear."
"This is how I give myself a painless injection."
Heather Johnson

"A helpful tip for newly diagnosed MS patients."
"Important advice on choosing MS medication "
Joyce Moore


This page is powered by Blogger. Isn't yours?

Saturday

 

The Ampyra (Fampridine) Upper Limb Study: Baseline clinical and electrophysiological data: STUDY

























Image Source: 2HANDSCLINIC



Aim:
To describe initial clinical and electrophysiological results from the Fampridine Upper Limb Study, conducted in patients with Multiple Sclerosis (MS) and upper limb impairment.

Methods:
This randomised, double-blinded placebo controlled trial of modified-release fampridine comprises three groups: patients on drug, patients on placebo and healthy controls. Baseline assessments conducted prior to initiation of drug (fampridine-MR 10 mg bd) or placebo included the following clinical tests: 9-hole peg test, manual grip strength, sensory discrimination capacity, visual acuity & contrast sensitivity, Fatigue Impact Scale score. Baseline electrophysiological tests included the following: visual evoked potential latency and amplitude, somatosensory evoked potential, median motor and sensory nerve conduction studies & F-waves, resting motor threshold, MEP latency, paired-pulse transcranial magnetic stimulation, MEP recruitment curves. Comparisons were made at baseline between MS patients and controls, and between patients with different MS subtypes (RRMS, PPMS, SPMS). Correlations were made between clinical and electrophysiological measures at baseline.

Results:
40 patients (60% female, median age 52 years) with MS and upper limb impairment and 20 healthy controls (60% female, median age 53 years) were studied. Of the patients, 9 had RRMS, 18 had SPMS and 13 had PPMS. The results of clinical measures of hand function (9-hole peg test, manual grip strength) and electrophysiological tests of nervous system function (VEP latency & amplitude, SSEP latency, MEP latency, resting motor threshold, MEP recruitment and PPTMS) are reported and compared between patients and controls and between patients with different subtypes of MS disease course.

Conclusion:
Evoked potentials and TMS measures differ between MS patients and healthy controls, with observable differences between patients with different subtypes of MS. Such electrophysiological markers may represent useful surrogate markers in clinical trials of symptomatic and disease-modifying therapies for MS.

Story Source: The above story is based on materials provided by SCIENCEDIRECT
Note: Materials may be edited for content and length 
Click here to read original article

Labels:



Go to Newer News Go to Older News